<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722239</url>
  </required_header>
  <id_info>
    <org_study_id>D1691C00012</org_study_id>
    <secondary_id>D1691C00012</secondary_id>
    <nct_id>NCT02722239</nct_id>
  </id_info>
  <brief_title>An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin Modified Release Film-coated Tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) Versus the Combined Use of Forxiga™ (Dapagliflozin), Film-coated Tablets, 10 mg (Bristol Myers Squibb Company, USA) and Two Glucophage® Long (Metformin), ER Tablets, 500 mg (Merck Santé S.A.S., France), Co-administered to Healthy Volunteers Under Standard Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate bioequivalence of fixed dose combination
      Dapagliflozin + Metformin modified -release, film-coated tablets, 10 mg + 1000 mg,
      (AstraZeneca AB, Sweden) versus Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg (Bristol
      Myers Squibb Company, USA) and Glucophage® long (Metformin), ER tablets, 1000 mg (2 x 500 mg)
      (Merck Santé S.A.S., France) which are already registered in the Russian Federation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised open-label crossover comparative, single center, two periods, clinical study of
      investigational drug and reference drugs bioequivalence evaluation with a single
      administration of the study drug (1 modified - release film-coated tablets of Dapagliflozin +
      Metformin or 1 film-coated tablets of Forxiga™ + 2 tablets ER of Glucophage® long) under fed
      condition in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2016</start_date>
  <completion_date type="Actual">May 5, 2016</completion_date>
  <primary_completion_date type="Actual">May 5, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax).</measure>
    <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the &quot;Concentration - Time&quot; Curve (AUC0-t)</measure>
    <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the &quot;Concentration - Time&quot; Curve (AUC0-∞)</measure>
    <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios</measure>
    <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
    <description>The drugs are considered bioequivalent if the 90% confidence intervals for the Test : Reference products geometric least squares mean ratios of AUC, Cmax и Cmax/AUC parameters are in the range of 80% - 125%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>AE information will be collected from the time of the first dosing to the last study procedure made in the hospital, approximately 1 month</time_frame>
    <description>Adverse events data for Dapagliflozin + Metformin, modified-release film-coated tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) and for co-administered Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg, (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), XR tablets, 500 mg/2 tablets (Merck Santé S.A.S, France)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>T/R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xigduo XR</intervention_name>
    <description>a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release</description>
    <arm_group_label>T/R</arm_group_label>
    <arm_group_label>R/T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin ER (Glucophage® long)</intervention_name>
    <description>co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
    <arm_group_label>T/R</arm_group_label>
    <arm_group_label>R/T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin (Forxiga)</intervention_name>
    <description>co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
    <arm_group_label>T/R</arm_group_label>
    <arm_group_label>R/T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The volunteer is able to understand the requirements of the study, to sign the
             informed consent form, and agrees with all the restrictions imposed in the course of
             the study;

          2. Male and female subjects aged 18-45, inclusive;

          3. Caucasian race;

          4. Body-mass index (BMI) within the range dated 18.5 to 30 kg/m2;

          5. Verified diagnosis &quot;healthy&quot; as confirmed by the results of standard clinical,
             laboratory, and instrumental evaluations;

          6. A negative pregnancy test at the Screening Visit for female subjects of childbearing
             potential.

             Postmenopausal (no menses for at least 1 year) or surgically sterile (bilateral tubal
             ligation, bilateral oophorectomy, or hysterectomy) females are exempted from the
             requirement. In case of using hormonal contraceptives, these should be withdrawn at
             least 2 months before the study;

          7. Volunteers' with preserved reproductive potential agree to use adequate contraception
             throughout the study and for 30 days thereafter

        Exclusion Criteria:

          1. Known hypersensitivity or intolerance to dapagliflozin or metformin or any other
             excipient of the study drugs;

          2. History of allergy to Na+ glucose co-transport inhibitor;

          3. Complicated allergic history including food intolerance;

          4. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption;

          5. Chronic diseases of the cardiovascular, bronchopulmonary, nervous, endocrine, or
             musculoskeletal systems, as well as diseases of the gastrointestinal tract, liver,
             kidneys, blood, immune system, mental disorders;

          6. Deviations from the normal parameters in clinical blood count analysis, biochemical
             blood analysis, urinalysis; vital signs;

          7. Mental, physical and other reasons that do not allow the subjects according to
             investigator's opinion to assess their behavior adequately, to follow correctly the
             requirements of the clinical study protocol and to assess the expected risks and
             possible discomfort;

          8. Organic brain damage, history of increased seizure activity;

          9. Changes on ECG (clinically significant);

         10. Systolic blood pressure (AD) measured in a sitting position, less than 100 mmHg or
             above 130 mmHg and / or diastolic blood pressure below 70 mm Hg or above 90 mmHg at
             screening or any time during the study;

         11. Heart rate less than 60 or more than 80 beats per minute at screening or prior to
             administration of the drug in each period of the study;

         12. Scheduled radioisotope or radiological examinations using iodinated contrast agents
             during &lt; 2 days before dosing;

         13. Rare hereditary diseases manifestating with fructose or sorbitol intolerance;

         14. Gastrointestinal tract surgery (except appendectomy);

         15. Acute infectious diseases less than 4 weeks before the start of the study;

         16. Regular medication (including dietary supplements and combination herbal medicinal
             products) and vitamins intake within 2 weeks (or 6 half-lives, whichever is longer)
             prior inclusion into the study and subject does not give agreement to refuse from this
             medication until the end of study;

         17. Administration of the medicines that have a significant effect on circulatory
             dynamics, liver function, etc. (barbiturates, omeprazol, zimetidin etc.) less than 30
             days before the start of the study;

         18. Blood donation (450 ml and more of blood or plasma) less than 2 months before the
             start of the study;

         19. Participation in another clinical study within 3 months before the start of the study;

         20. Alcohol intake &gt; 10 units of alcohol per week (1 unit of alcohol - 500 ml of beer, 200
             ml of dry wine or 50 ml of strong alcoholic beverages) or history of alcohol abuse,
             narcomania or other drug abuse.

         21. Use of alcohol and/or caffeinated and xanthine containing substances (for example,
             coffee, tea, colas, energetic drinks), chocolate as well as citrus fruits and
             cranberry (including juices, fruit drinks, etc.) 72 hours prior and throughout the
             study.

         22. Smoker (&gt;10 cigarettes per day) and/or inability to refrain from smoking on Period I
             and Period II

         23. Special diets (e.g. vegetarians or hypocaloric diet [ less than 1000 cal/day]) or
             lifestyle (including night work and extreme physical activities, such as sports or
             weight lifting), which may impede the study conduction and monitoring;

         24. Positive screening blood test for hepatitis B surface antigen (HBsAg), hepatitis C
             (HCV) antibody, human immunodeficiency virus (HIV-1or HIV-2 antibodies) and / or
             syphilis (RW);

         25. A positive drug urine screening (cocaine, opiates, cannabis, barbiturates,
             amphetamines);

         26. A positive alcohol breath test;

         27. Dehydration due to diarrhea, vomiting or another cause during the last 24 hours before
             the start of the study;

         28. There is any concern by the investigator regarding the safe participation of the
             subject in the study or for any other reason; the investigator considers the subject
             ineligible for the study.

         29. Breast-feeding period;

         30. For women - Use of hormonal contraceptives for 2 months before the study start;

         31. Female volunteers with childbearing potential, having unprotected sexual intercourse
             with any unsterilized male partner (i.e., a man that is not sterilized by vasectomy
             for at least 6 months) for 30 days before receiving study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <results_first_submitted>April 21, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2018</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xigduo;</keyword>
  <keyword>bioequivalence;</keyword>
  <keyword>crossover;</keyword>
  <keyword>Russia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from one medical clinic located in Moscow, Russia in March and April 2016.</recruitment_details>
      <pre_assignment_details>46 subjects were screened, 40 randomized (2 did not meet inclusion criteria and 4 were back-up volunteers).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T Drug First / Then Drug R</title>
          <description>Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period took the study test product (Т), and on the second study period after wash out period of 7 days the volunteers were given the Reference product (R)</description>
        </group>
        <group group_id="P2">
          <title>R Drug First / Then Drug T</title>
          <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 were administered with the study drug in reverse order. It means that group 1 took the study products in sequence T-R and group 2 in the sequence R-T.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention (1 Day)</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The age range of the study healthy volunteers was 19-44 years.</population>
      <group_list>
        <group group_id="B1">
          <title>T Drug First / Then Drug R</title>
          <description>Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period took the study test product (Т), and on the second study period after wash out period of 7 days the volunteers were given the Reference product (R)</description>
        </group>
        <group group_id="B2">
          <title>R Drug First / Then Drug T</title>
          <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 were administered with the study drug in reverse order. It means that group 1 took the study products in sequence T-R and group 2 in the sequence R-T.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (years): Mean ± Standard Deviation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="7.7"/>
                    <measurement group_id="B2" value="30.8" spread="8.7"/>
                    <measurement group_id="B3" value="30.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>between 18 and 45 years (inclusive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax).</title>
        <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Product (T)</title>
            <description>Test Product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release.</description>
          </group>
          <group group_id="O2">
            <title>Reference Product (R)</title>
            <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax).</title>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin Cmax [ug/ml]: Mean (± SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.883" spread="25.302"/>
                    <measurement group_id="O2" value="95.975" spread="25.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin Cmax [ug/ml]: Mean (± SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1030.83" spread="258.910"/>
                    <measurement group_id="O2" value="986.93" spread="255.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the “Concentration – Time” Curve (AUC0-t)</title>
        <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Product (T)</title>
            <description>Test Product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release.</description>
          </group>
          <group group_id="O2">
            <title>Reference Product (R)</title>
            <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the “Concentration – Time” Curve (AUC0-t)</title>
          <units>ug/mL*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin AUC0-t [ug/mL*h]: Mean (± SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505.964" spread="130.420"/>
                    <measurement group_id="O2" value="511.293" spread="127.715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin AUC0-t [ug/mL*h]: Mean (± SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8858.52" spread="2998.49"/>
                    <measurement group_id="O2" value="9286.92" spread="3222.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the “Concentration – Time” Curve (AUC0-∞)</title>
        <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Product (T)</title>
            <description>Test Product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release.</description>
          </group>
          <group group_id="O2">
            <title>Reference Product (R)</title>
            <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the “Concentration – Time” Curve (AUC0-∞)</title>
          <units>ug/mL*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin AUC0-∞ [ug/mL*h]: Mean (± SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="521.295" spread="136.036"/>
                    <measurement group_id="O2" value="532.556" spread="144.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin AUC0-∞ [ug/mL*h]: Mean (± SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9408.51" spread="3373.65"/>
                    <measurement group_id="O2" value="9612.23" spread="3440.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios</title>
        <description>The drugs are considered bioequivalent if the 90% confidence intervals for the Test : Reference products geometric least squares mean ratios of AUC, Cmax и Cmax/AUC parameters are in the range of 80% - 125%.</description>
        <time_frame>Blood sampling 0 h, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours and 72 hours after the dosing. Time interval for sampling is provided with pharmacokinetic characteristics of the product.</time_frame>
        <population>The Arms/Groups are combined because the main study goal was to compare the bioequivalence of the study drug and the reference drug which were intaken by all volunteers regardless of the group.</population>
        <group_list>
          <group group_id="O1">
            <title>T Drug vs R Drug</title>
            <description>Ratio of Test product (a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release) and Reference product (co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long)).</description>
          </group>
        </group_list>
        <measure>
          <title>Bioequivalence Consideration: 90% Confidence Intervals for the Test:Reference Geometric Least Squares Mean Ratios</title>
          <description>The drugs are considered bioequivalent if the 90% confidence intervals for the Test : Reference products geometric least squares mean ratios of AUC, Cmax и Cmax/AUC parameters are in the range of 80% - 125%.</description>
          <population>The Arms/Groups are combined because the main study goal was to compare the bioequivalence of the study drug and the reference drug which were intaken by all volunteers regardless of the group.</population>
          <units>Geometric least squares mean ratio (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dapagliflozin AUC0-t %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0829" lower_limit="95.943" upper_limit="102.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dapagliflozin Cmax %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7712" lower_limit="87.887" upper_limit="102.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dapagliflozin Cmax/AUC0-t %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6484" lower_limit="89.102" upper_limit="102.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin AUC0-t %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9105" lower_limit="89.492" upper_limit="102.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin Cmax %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3772" lower_limit="98.492" upper_limit="110.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin Cmax/AUC0-t %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.8277" lower_limit="101.607" upper_limit="116.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Adverse events data for Dapagliflozin + Metformin, modified-release film-coated tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) and for co-administered Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg, (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), XR tablets, 500 mg/2 tablets (Merck Santé S.A.S, France)</description>
        <time_frame>AE information will be collected from the time of the first dosing to the last study procedure made in the hospital, approximately 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Product (T)</title>
            <description>Test Product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release.</description>
          </group>
          <group group_id="O2">
            <title>Reference Product (R)</title>
            <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events data for Dapagliflozin + Metformin, modified-release film-coated tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) and for co-administered Forxiga™ (Dapagliflozin), film-coated tablets, 10 mg, (Bristol Myers Squibb Company, USA) and Glucophage® long (Metformin), XR tablets, 500 mg/2 tablets (Merck Santé S.A.S, France)</description>
          <units>adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <desc>According to the local regulatory authorities request any (even clinically insignificant) laboratory abnormalities have been interpreted as adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Product (T)</title>
          <description>Test Product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release.</description>
        </group>
        <group group_id="E2">
          <title>Reference Product (R)</title>
          <description>Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <description>The events were associated with dapagliflozin mechanism of action.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Haematocrit increased in hematology</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Specific gravity urine decreased</sub_title>
                <description>The events were associated with dapagliflozin mechanism of action.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pH urine decreased</sub_title>
                <description>The events were associated with dapagliflozin mechanism of action.</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI signed the Protocol and agreed to conform fully to the Protocol requirements. According to the Protocol the PI should inform the Sponsor in writing beforehand and provide the sponsor with all manuscripts or abstracts before submitting them to the editorial office or scientific expert board, and obtain a written permission from the Sponsor. The period is not mentioned.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadiya Rizvanova</name_or_title>
      <organization>Biocard Research LLC</organization>
      <phone>+74993088278</phone>
      <email>n.rizvanova@biocard.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

